Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group.

Allergy·2023

Same author

Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome.

Journal of clinical immunology·2023

Same author

Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort.

Thorax·2023

Same author

Imaging Features of Autoimmune Disease-Related Interstitial Lung Diseases.

Journal of thoracic imaging·2023

Same author

Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.

Annals of the rheumatic diseases·2023

Same author

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).

BMJ open respiratory research·2023

Search research articles

Related Experiment Videos

Update on bioagent therapy in sarcoidosis.

Vincent Cottin¹

¹Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Pneumologie - Centre de référence des maladies rares pulmonaires, Université de Lyon, Université Lyon I INRA, UMR754, IFR128, Lyon France.

F1000 Medicine Reports

|October 16, 2010

Summary

Corticosteroids remain the primary treatment for sarcoidosis. Alternative therapies like methotrexate and infliximab show promise for refractory cases or severe manifestations, but require further study.

Related Experiment Videos

Area of Science:

Pulmonary Medicine
Immunology

Background:

Corticosteroids are the standard systemic therapy for sarcoidosis.
Refractory cases or those requiring long-term treatment pose challenges.

Purpose of the Study:

To review current and alternative treatment options for sarcoidosis.
To evaluate the role of biologics, specifically infliximab, in managing sarcoidosis.

Main Methods:

Literature review of treatment strategies for sarcoidosis.
Analysis of studies on alternative agents and biologic therapies.

Main Results:

Methotrexate is a viable alternative for refractory sarcoidosis.
Infliximab may offer modest benefits for steroid-resistant pulmonary sarcoidosis.
Infliximab's role in severe extrapulmonary sarcoidosis warrants careful risk-benefit assessment.

Conclusions:

Corticosteroids remain central to sarcoidosis management.
Methotrexate and infliximab represent important alternatives for specific patient groups.
Further research is essential to establish the definitive role and safety of infliximab in pulmonary sarcoidosis.